A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Autor: Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers
Přispěvatelé: Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Erasmus MC other, Medical Oncology
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Cancers, 15(11):2922. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 15, 11
Cancers, 15
van Not, O J, Wind, T T, Ismail, R K, Bhattacharya, A, Jalving, M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Haanen, J B, Kapiteijn, E, Bloem, M, Piersma, D, van Rijn, R S, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Blokx, W A M, Suijkerbuijk, K P M, Fehrmann, R S N & Hospers, G A P 2023, ' A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors ', Cancers, vol. 15, no. 11, 2922 . https://doi.org/10.3390/cancers15112922
Cancers; Volume 15; Issue 11; Pages: 2922
ISSN: 2072-6694
DOI: 10.3390/cancers15112922
Popis: Contains fulltext : 293454.pdf (Publisher’s version ) (Open Access) The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab-nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients' survival based on their baseline and disease characteristics.
Databáze: OpenAIRE
Externí odkaz: